President Trump nominated White House domestic policy aide and physician Heidi Overton on August 19, 2026, to serve as FDA Commissioner, filling the vacancy created by Marty Makary’s May resignation. The Senate must confirm the nominee through the Health, Education, Labor and Pensions Committee before a full floor vote. Senate HELP Chairman Bill Cassidy immediately expressed strong reservations, citing Overton’s involvement in a recent executive order on childhood vaccines as “almost disqualifying.” With Republicans holding the Senate majority, the confirmation timeline depends on committee scheduling, potential holds, and broader administration priorities on health regulation. No floor vote has been scheduled, and acting Commissioner Kyle Diamantas continues in the role.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日新規
2026/09/30
9月30日
48%
10月31日
52%
11月30日
53%
12月31日
74%
$597 Vol.
9月30日
$575 Vol.
48%
10月31日
$11 Vol.
52%
11月30日
$0 Vol.
53%
12月31日
$11 Vol.
74%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide and physician Heidi Overton on August 19, 2026, to serve as FDA Commissioner, filling the vacancy created by Marty Makary’s May resignation. The Senate must confirm the nominee through the Health, Education, Labor and Pensions Committee before a full floor vote. Senate HELP Chairman Bill Cassidy immediately expressed strong reservations, citing Overton’s involvement in a recent executive order on childhood vaccines as “almost disqualifying.” With Republicans holding the Senate majority, the confirmation timeline depends on committee scheduling, potential holds, and broader administration priorities on health regulation. No floor vote has been scheduled, and acting Commissioner Kyle Diamantas continues in the role.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
マーケット開始日： Aug 20, 2026, 5:43 PM ET
音量
$597終了日
2027/01/01マーケット開始日
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump nominated White House domestic policy aide and physician Heidi Overton on August 19, 2026, to serve as FDA Commissioner, filling the vacancy created by Marty Makary’s May resignation. The Senate must confirm the nominee through the Health, Education, Labor and Pensions Committee before a full floor vote. Senate HELP Chairman Bill Cassidy immediately expressed strong reservations, citing Overton’s involvement in a recent executive order on childhood vaccines as “almost disqualifying.” With Republicans holding the Senate majority, the confirmation timeline depends on committee scheduling, potential holds, and broader administration priorities on health regulation. No floor vote has been scheduled, and acting Commissioner Kyle Diamantas continues in the role.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
音量
$597終了日
2027/01/01マーケット開始日
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump nominated White House domestic policy aide and physician Heidi Overton on August 19, 2026, to serve as FDA Commissioner, filling the vacancy created by Marty Makary’s May resignation. The Senate must confirm the nominee through the Health, Education, Labor and Pensions Committee before a full floor vote. Senate HELP Chairman Bill Cassidy immediately expressed strong reservations, citing Overton’s involvement in a recent executive order on childhood vaccines as “almost disqualifying.” With Republicans holding the Senate majority, the confirmation timeline depends on committee scheduling, potential holds, and broader administration priorities on health regulation. No floor vote has been scheduled, and acting Commissioner Kyle Diamantas continues in the role.
Polymarketデータを参照したAI生成の実験的な要約。これは取引アドバイスではなく、このマーケットの解決方法には一切関係ありません。 · 更新日
外部リンクに注意してください。
外部リンクに注意してください。
よくある質問